The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Jansen, Christian ^a   Eischeid, Hannah ^b   Goertzen, Jan ^a   Schierwagen, Robert ^a   Anadol, Evrim ^a   Strassburg, Christian P ^a   Sauerbruch, Tilman ^a   Odenthal, Margarete ^b   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; GAMMA GLUTAMYLTRANSFERASE; MICRORNA 34A; MICRORNA; MIRN34 MICRORNA, HUMAN;

ADULT; AGED; ANATOMICAL VARIATION; ARTERIAL PRESSURE; ARTICLE; ASCITES; BLEEDING; BLOOD FLOW VELOCITY; CHRONIC LIVER DISEASE; CONGESTION INDEX; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HUMAN; LIVER CIRRHOSIS; LIVER VEIN; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; POLYMERASE CHAIN REACTION; PORTAL HEPATIC PRESSURE GRADIENT; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN BLOOD FLOW; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURVIVAL; SURVIVAL RATE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT OUTCOME; BLOOD; GENE EXPRESSION; GENETICS; HYPERTENSION, PORTAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; BIOMARKERS; FEMALE; GENE EXPRESSION; HEPATIC VEINS; HUMANS; HYPERTENSION, PORTAL; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MALE; MICRORNAS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PORTAL VEIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84904864046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103779     Document Type: Article

References (36)

1. Bosch J, Garcia-Pagan JC (2000) Complications of cirrhosis. I. Portal hypertension. J Hepatol 32: 141-156. (Pubitemid 30123631)
2. Schuppan D, Afdhal NH (2008) Liver cirrhosis. Lancet 371: 838-851. (Pubitemid 351323895)
3. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, et al. (2000) Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 47: 288-295. (Pubitemid 30489776)
4. Salerno F, Camma C, Enea M, Rossle M, Wong F (2007) Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133: 825-834. (Pubitemid 47374134)
5. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, et al. (2010) Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 362: 2370-2379.
6. Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, et al. (2013) Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 58: 45-50.
7. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L (2011) Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6: e23937.
8. Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, et al. (2010) Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 90: 1437-1446.
9. Wang YT, Tsai PC, Liao YC, Hsu CY, Juo SH (2013) Circulating microRNAs have a sex-specific association with metabolic syndrome. J Biomed Sci 20: 72.
10. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, et al. (2013) Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 424: 99-103.
11. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
12. Li N, Fu H, Tie Y, Hu Z, Kong W, et al. (2009) miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275: 44-53.
13. Locke JM, Lango Allen H, Harries LW (2014) A rare SNP in pre-miR-34a is associated with increased levels of miR-34a in pancreatic beta cells. Acta Diabetol 51: 325-329.
14. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, et al. (2012) TGF-beta-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 22: 291-303.
15. Trebicka J, Krag A, Gansweid S, Appenrodt B, Schiedermaier P, et al. (2011) Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 23: 1218-1225.
16. Trebicka J, Krag A, Gansweid S, Schiedermaier P, Strunk HM, et al. (2013) Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PLoS One 8: e83341.
17. Moriyasu F, Nishida O, Ban N, Nakamura T, Sakai M, et al. (1986) "Congestion index" of the portal vein. AJR Am J Roentgenol 146: 735-739.
18. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, et al. (2013) Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 58: 234-239.
19. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, et al. (2005) Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54: 1174-1179. (Pubitemid 41025916)
20. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, et al. (1999) The long-term course of chronic hepatitis B. Hepatology 30: 257-264. (Pubitemid 29300594)
21. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, et al. (2005) MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41: 353-358. (Pubitemid 40165379)
22. Alexander JF, Lischner MW, Galambos JT (1971) Natural history of alcoholic hepatitis. II. The long-term prognosis. Am J Gastroenterol 56: 515-525.
23. Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53: 744-749. (Pubitemid 38561455)
24. Lee YM, Kaplan MM (2005) The natural history of PBC: has it changed? Semin Liver Dis 25: 321-326.
25. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419. (Pubitemid 29258890)
26. Wieckowska A, McCullough AJ, Feldstein AE (2007) Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46: 582-589. (Pubitemid 47344794)
27. McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40 Suppl 1: S17-29.
28. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, et al. (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695. (Pubitemid 28549142)
29. Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, et al. (1991) Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 86: 210-216.
30. de Franchis R (2010) Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53: 762-768.
31. Reynolds TB, Geller HM, Kuzma OT, Redeker AG (1960) Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 263: 734-739.
32. Boyer TD, Triger DR, Horisawa M, Redeker AG, Reynolds TB (1977) Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology 72: 584-589. (Pubitemid 8097593)
33. Ekataksin W, Kaneda K (1999) Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 19: 359-382. (Pubitemid 30032639)
34. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, et al. (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31: 864-871. (Pubitemid 30169932)
35. Bureau C, Metivier S, D'Amico M, Peron JM, Otal P, et al. (2011) Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol 54: 901-907.
36. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, et al. (2005) Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353: 2254-2261. (Pubitemid 41697288)